Navidea Biopharma (NAVB) Tops Q4 EPS by 2c

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $4.29 million versus the consensus estimate of $4.06 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank